Free EU-Wide Shipping on Orders Over €200
This product is intended solely for use as a research chemical in vitro and laboratory experimentation by licensed, qualified professionals.
Ipamorelin
39,99 €
Ipamorelin is a selective growth hormone secretagogue pentapeptide. Researched for targeted GH release without significant effects on cortisol, prolactin, or appetite. 10mg lyophilized powder, ≥99% purity.
Bulk Discounts
- Buy 3+ for 37,99 € each and save 5%
- Buy 5+ for 35,99 € each and save 10%
- Buy 10+ for 33,99 € each and save 15%
Ships Tomorrow - order cutoff passed
Free EU Shipping on orders over €200
Third party tested
Ipamorelin—
39,99 €
Advanced Laboratory Testing
HPLC
Mass Spec
≥99% Purity
Secure
Fast Ship
EU Based
Characteristics
| Molecular Formula | C38H49N9O5 |
| CAS | 170851-70-4 |
| Molar Mass | 711.85 g/mol |
| Amino Acid Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Synonyms | NNC 26-0161, Ipamorelin acetate |
| Solubility | Soluble in water |
| Organoleptic Profile | White powder |
| Physical Form | Lyophilized powder |
How does Ipamorelin work?
Ipamorelin is a pentapeptide growth hormone secretagogue that selectively binds the ghrelin/GHS receptor (GHSR) to stimulate growth hormone release from the anterior pituitary.
Unlike other GH secretagogues such as GHRP-6 and GHRP-2, Ipamorelin demonstrates high selectivity — it stimulates GH release in a dose-dependent manner without significantly affecting cortisol, prolactin, FSH, LH, or TSH levels. This selectivity makes it valuable for studying isolated GH axis function.
Ipamorelin preserves the natural pulsatile pattern of GH release rather than creating a sustained elevation. Research indicates it does not significantly increase appetite (unlike ghrelin and GHRP-6), making it a cleaner pharmacological tool for GH research.
Benefits
- Selective GH Release: Stimulates growth hormone release without affecting cortisol, prolactin, or other pituitary hormones
- Pulsatile Pattern: Preserves natural GH pulsatile release pattern rather than sustained elevation
- Body Composition: Improved body composition metrics including lean mass and bone density in preclinical models
- Recovery Research: Studied for tissue repair and recovery through GH-mediated pathways
- Clean Pharmacology: Minimal appetite stimulation compared to other GH secretagogues like GHRP-6
Side Effects
Ipamorelin is generally considered safe and well tolerated when used in research settings. However, as with any substance, there is a potential for side effects, particularly when used at high concentrations or for prolonged periods.
- Injection Site Reactions: Mild redness or discomfort at the injection site
- Headache: Transient headache reported in some research subjects
- Water Retention: Mild water retention possible during initial administration
- Numbness/Tingling: Temporary numbness or tingling in extremities reported in some studies
It's important to note that the safety and efficacy of Ipamorelin for human use have not been fully established, and more research is needed to determine the long-term effects of this peptide complex.
Summary
Ipamorelin (NNC 26-0161) is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk in the 1990s. It was designed as a selective agonist of the ghrelin/GHS receptor.
Ipamorelin is distinguished from other GH secretagogues by its high selectivity for GH release without significant effects on other pituitary hormones. This pharmacological profile has made it one of the most widely studied GH secretagogues in preclinical research.
Certificate of Analysis (COA) available upon request. Each batch is tested via HPLC for purity and Mass Spectrometry for identity confirmation.
References
- 1Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue" European Journal of Endocrinology. 1998. doi:10.1530/eje.0.1390552
- 2Johansen PB, et al. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats" Growth Hormone & IGF Research. 1999. doi:10.1054/ghir.1999.9998
- 3Beck DE, et al. "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for postoperative ileus" Journal of Gastrointestinal Surgery. 2014. doi:10.1007/s11605-014-2524-y
Resource
All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration or the European Medicines Agency. Products are not intended to diagnose, treat, cure, or prevent any disease.